Background: Palliative care in outpatient setting has been shown to promote better symptom management and transition to hospice care among patients with advanced cancer. Nevertheless, specialized palliative care is rarely provided at cancer centers in Korea. Herein, we aimed to assess aggressiveness of end-of-life care for patients with metastatic colorectal cancer according to the use of outpatient palliative care (OPC) at a single cancer center in Korea. Methods: We performed a retrospective medical record review for 132 patients with metastatic colorectal cancer who died between 2011 and 2014. Fifty patients used OPC (OPC group), while 82 patients did not (non-OPC group). Indicators of aggressiveness of end-of-life care including chemotherapy use, emergency department visits, hospitalization, and utilization of hospice care were analyzed according to the use of OPC. Results: More patients in the OPC group were admitted to hospice than those in the non-OPC group (32% vs 17%, P ¼ .047). The mean of inpatient days within 30 days of death was shorter for the OPC group than the non-OPC group (4.02 days vs 7.77 days, respectively, P ¼ .032). There were no differences in the proportions of patients who received chemotherapy and visited the emergency department within 30 days from death. Conclusion: Among patients with metastatic colorectal cancer, OPC was associated with shorter inpatient days near death and greater hospice utilization. Further prospective studies are needed to evaluate the impact of OPC on end-of-life care in Korea.
Introduction
Colorectal cancer is the third most common cancer worldwide and in Korea, where increases in colorectal cancer incidence and mortality have drawn greater concern as public health issues. 1, 2 Almost half of all patients who are diagnosed with colorectal cancer eventually develop metastatic disease. 3 Although techniques for curative surgery have improved and biological agents, such as bevacizumab or cetuximab, have helped prolong overall survival, only about 10% of all patients with metastatic colorectal cancer (mCRC) survive more than 5 years. 4 Patients with mCRC reportedly express more optimistic expectations on the curative potential of palliative chemotherapy than those with lung cancer. 5 Unrealistic expectations among patients with mCRC may be explained by relatively better responses to chemotherapy and longer survival for mCRC than for lung cancer. Meanwhile, however, the overestimation of prognosis has been found to be associated with the decreased utilization of hospice. 6 Additional research also suggests that patients with unrealistic expectations concerning their prognosis may be more likely to delay advance care planning, which would further limit their likelihood of receiving hospice care.
indicators of aggressiveness of care near death. 2, 8, 9 In Korea, aggressive end-of-life (EOL) care is prominent and is exemplified by late referral to hospice and prevalent use of chemotherapy near death. [10] [11] [12] [13] Moreover, only a few cancer centers throughout Korea operate an outpatient clinic for specialized palliative care.
The National Cancer Center of Korea (NCC Korea) has offered outpatient palliative care (OPC) services via a palliative care team trained in hospice palliative care. Reviewing medical records for patients with mCRC, we aimed to assess aggressiveness of EOL care according to use of OPC services.
Methods

Study Patients
We retrospectively reviewed medical records of patients with mCRC treated at NCC Korea. From January 2011 to September 2014, a total of 568 patients with mCRC were identified from a clinical registry at the Division of Medical Oncology at the Center for Colorectal Cancer, NCC Korea. Among these individuals, we extracted data for those who had died and whose medical records within 90 days from their death were available as of October 2014. Among the 568 patients, 367 were alive, 57 were unknown for survival status, and 12 were lost to follow-up before 90 days prior to their death. Finally, 132 patients were included in this study (Figure 1 ). Among these, 50 patients used OPC service (OPC group), and 82 patients were not seen by palliative care team at outpatient office (non-OPC group). Those who were given palliative care as an inpatient first and visited OPC clinic as a followup were assigned to the non-OPC group. This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the institutional review board of NCC Korea (IRB No. NCC2015-0016).
Outpatient Palliative Care
Outpatient palliative care was provided by the palliative care team at NCC Korea. The team consists of 2 physicians (H.J.J. and Y.J.C.) and a nurse (E.J.N.) who have all completed palliative care training organized by the Ministry of Health & Welfare, Republic of Korea. Outpatient palliative care routinely includes managing a patient's physical and psychological symptoms, exploring awareness of an individual's illness for both patient and their family members, and introducing patients to hospice care facilities. Patients were routinely recommended to receive OPC services by medical oncologists (S.Y.K. and J.Y.B.), usually after the completion of secondor third-line chemotherapy. Patients were also scheduled to visit a medical oncology clinic for the continuity of care with their oncologists, even during the follow-up at the OPC clinic.
Data Collection and Outcome Measures
Baseline characteristics for each patient, including age, sex, comorbidities, education level, and performance status at initial diagnosis of mCRC, as well as disease-related factors of primary disease site in the colorectum, KRAS mutation status, and number of metastatic organs at the time of initial diagnosis of mCRC, were collected. Chemotherapy regimens in a metastatic setting, use of targeted agents (bevacizumab, cetuximab, panitumumab, and regorafenib), date of last chemotherapy, date of diagnosis of terminal mCRC, date of palliative care consultation in an outpatient or inpatient setting, frequency of hospitalization, visit to an emergency department (ED), and admission to an intensive care unit (ICU) were also collected from medical records. Adjuvant chemotherapy was regarded as first-line treatment, if metastatic or locoregional progression occurred within 6 months after completion thereof. Diagnosis of terminal mCRC was made by medical oncologists (S.Y.K. and J.Y.B.), when no more effective chemotherapeutic option was available or if the patient would likely not tolerate further chemotherapy. Performance status at the time of diagnosis of terminal mCRC and circumstances of death, including place of death, receiving cardiopulmonary resuscitation (CPR), and patient or family consent to a do-not-resuscitate order, were also reviewed. Information on utilization of hospice care was obtained from the Korean Terminal Cancer Patient Information System (KTCPIS), a national database operated by the Ministry of Health and Welfare, Republic of Korea.
Aggressiveness of EOL care was estimated using the following indicators-any dose of chemotherapy, any ED visits, and any hospitalization within 30 days from death; the inpatient days within 30 days from death; the utilization of hospice care; and the length of stay in hospice. The overall survival was defined as the date of diagnosis of mCRC to the date of death.
Statistical Analysis
General characteristics of the participants were summarized as percentages and means with standard deviation (SD). The w 2 test or Fisher exact test was used to compare categorical variables between the OPC and non-OPC groups as appropriate. Continuous variables were compared with the Mann-Whitney test. The Kaplan-Meier method was used to estimate the overall survival after diagnosis of mCRC; the overall survival between the 2 groups was compared to the log-rank test. The associations of OPC use with the utilization of hospice care were evaluated using logistic regression analyses with adjustment for other putatively relevant clinical factors. All P values < .05 were considered statistically significant. Statistical analyses were performed using STATA software, v12.0 (StataCorp, College Station, Texas). Figure 1 summarizes the case selection process. Baseline characteristics of age, performance status, comorbidities, and education level showed no significant difference between the 2 groups, as described in Table 1 . Clinical factors of primary disease site of the colorectum, number of metastatic sites, and KRAS mutation status also showed similar distributions between the 2 groups (Table 1) . Table 2 presents details on the anticancer treatments for the study participants. The extent of treatment for mCRC, including chemotherapy, radiotherapy, resection of primary tumor, and metastasectomy, did not significantly differ between the 2 groups. Usage of cytotoxic agents was also similar, while targeted agents, especially anti-epidermal growth factor receptor (EGFR) antibodies, tended to be less frequently applied to patients in the OPC group than in the non-OPC group. Consistently, more patients in the non-OPC group received targeted agents as their last line of chemotherapy than those in the OPC group.
Results
Patient Characteristics
Treatment for mCRC
Diagnosis of Terminal Disease and Palliative Care Consultation
The median interval from diagnosis of mCRC to diagnosis of terminal disease was 9.8 months in the OPC group and 11.9 months in the non-OPC group (P ¼ .930). Performance status at terminal diagnosis was Eastern Cooperative Oncology Group (ECOG) Scale 2 or worse in 56% of patients in the OPC group and 68% of patients in the non-OPC group (P ¼ .201). Among 102 patients who had used any type of palliative care service (inpatient or outpatient), most were referred after being diagnosed with terminal mCRC; only 14 (13.7%; 3 in the OPC group and 11 in the non-OPC group) were referred before being diagnosed with terminal mCRC. The mean number of visits to the OPC clinic for individuals in the OPC group was 3.1 (SD: 5.54, range: 1-39). Twelve (14.6%) patients in the non-OPC group received palliative care at the OPC clinic as part of their follow-up after inpatient consultation. Visit to the OPC clinic paralleled visits to the medical oncology clinic in 57 (92%) of all 62 patients who underwent follow-up at the OPC clinic. Table 3 lists the indicators of aggressiveness of EOL care of each group. Chemotherapy, ED visits, and any hospitalization within 30 days from death were not significantly different between the 2 study groups. The use of chemotherapy and episodes of hospitalization within 30 days from death tended to be lower in the OPC group. The average inpatient stay within 30 days from death was significantly shorter for the OPC group than for the non-OPC group (4.0 vs 7.8, P ¼ .032). Inpatient stay >7 days was more frequent in non-OPC group (39% vs 22%, P ¼ .043). More patients in the OPC group utilized hospice care than those in the non-OPC group (32.0% vs 17.1%, P ¼ .047). Length of stay in hospice was similar for the 2 groups, and 2 patients (one of OPC group and the other of non-OPC group) admitted to inpatient hospice within 3 days before death. Only 1 patient in the OPC group was admitted to the ICU within 30 days from death due to underlying asthma; CPR was done for 2 patients (one of OPC group and the other of non-OPC group), and the informed consent for do-not-resuscitate order was obtained in similar proportions of each group. In univariate analysis, the utilization of hospice care had no significant association with age, gender, comorbidities, education level, administered lines of chemotherapy, use of anti-EGFR antibodies, or the use of targeted agents as the last chemotherapy. Poor performance at diagnosis of terminal disease (ECOG 2 or worse) was associated with decreased hospice utilization (hazard ratio [HR]: 0.42, P ¼ .043), and receiving OPC was associated with increased hospice utilization (HR: 2.28, P ¼ .050). Nevertheless, multivariable analysis revealed neither OPC (P ¼ .073) nor performance at diagnosis of terminal disease (P ¼ .075) to be significantly associated with the utilization of hospice care. As for hospitalization 7 days within the last month, college degree and above (HR: 2.48, P < .001), use of anti-EGFR antibodies (HR: 2.32, P ¼ .057), and OPC (HR: 0.44, P ¼ .045) entered multivariable analysis, which showed a significant association with education level of college degree and above (HR: 2.37, P ¼ .001) and insignificant relationship with OPC (HR: 0.52, P ¼ .147).
Aggressiveness of EOL Care and Survival
The overall survival was 14 months in both groups (P ¼ .315). Survival after diagnosis of terminal mCRC was 3.5 months in the OPC group and 1.8 months in the non-OPC group (P ¼ .059).
Discussion
Our study investigated the associations of aggressiveness of EOL care with OPC service, focusing on patients with mCRC. In doing so, we found that patients who received OPC were more likely to use hospice care and spend less days in hospital near death.
Although the quality of EOL care is hard to measure or validate, there is a consensus that avoiding overly aggressive cancer treatments including chemotherapy, hospitalization, and ICU care is of the utmost importance in this period. 14, 15 However, failure to transit from anticancer treatment to palliative care in appropriate stage of disease course often results in unnecessary life-sustaining treatment near death. Early palliative care from the diagnosis of advanced cancer has been suggested to be the way to improve patients' quality of life and to ameliorate indicators of aggressive EOL care. 8, 16 Outpatient palliative clinic is essential for the delivery of early palliative care and has shown to improve cancer-related symptoms and quality of life. 17, 18 However, OPC is rarely offered by cancer centers in Korea. Although many cancer centers are equipped with inpatient palliative care services, outpatient service is rarely specialized for palliative care. Usually medical oncology outpatient services provide supportive care, which is hardly supported by palliative care teams or by an interdisciplinary approach in most Korean cancer centers. However, routine oncologic care is limited in its ability to address patient-centered issues, such as illness perceptions, coping with disease, and EOL planning. 19 Indeed, the lack or rarity of specialized OPC services could be one of the barriers of transition to palliative care and poor quality of EOL care in Korea.
The incidence of mCRC is rapidly increasing in Korea, with a median survival ranging from 18 to 30 months with cytotoxic chemotherapy and targeted therapy. Effective chemotherapeutic options, however, are generally limited after second-line therapy for patients with mCRC, and the survival of chemorefractory patients is around 5 months. 20 Thus, patients tend to show greater needs for palliative care after secondline therapy. In the present study, most of the referrals to palliative care occurred after administration of second-line treatment.
Our study showed that receiving OPC is associated with increased utilization of hospice facilities and shorter inpatient days within 30 days from death. At OPC, patients and family members are routinely explained about the utilization of hospice facility. Therefore, it is possible that patients in the OPC group could plan and decide on hospice utilization earlier than the non-OPC group, which could lead to shorter hospital stay. Low utilization of hospice facilities, in addition to late referral, is a significant problem in EOL care in Korea. 10, 21, 22 Utilization of hospice facilities among patients with cancer is gradually increasing in Korea, although it is still low. In 2012, 11.9% of all patients who died of cancer in Korea received EOL care at a hospice facility, 21 while greater than 40% of deaths were served by a hospice facility in 2011 in the United States. 23 The result of this study suggests that OPC could be a way to solve those low hospice utilization rates, and it is consistent with higher enrollment in hospice care among patients receiving early palliative care, compared to those receiving standard routine care in a randomized trial. 16 Nevertheless, in the present study, the mean length of stay in hospice was 20 days for the OPC and the non-OPC groups, which was similar to the average of 18 days in a study using data from the KTCPIS. 10 This suggests that late referral to hospice still needs to be overcome.
However, in multivariable analysis, referral to OPC didn't show significant association with increased hospice utilization. Aside from small number of participants, this could have been influenced by some practical barriers, especially the limited availability of hospice facility during our study period. Until the end of 2014, there was only 1 hospice facility in the city where our institution is located and there were a total of 57 facilities across Korea, most of which were concentrated at capital city, Seoul.
Hospitalization near death is an essential indicator of aggressiveness of care; it is associated with poor quality of life among dying patients 15 and increased health-care costs. 24 Across the globe, Korea is one of the countries where the proportion of hospital as a place of death is the highest, 25 suggesting hospitalization near death is quite prevalent. Palliative intervention could be an option to ameliorate this situation by reducing the cost and the length of hospital stay, as a prospective cohort study showed. 26 In this study, any hospitalization within 30 days from death tended to be rarer in the OPC group, although it did not show statistical significance. The average inpatient days during last months were significantly shorter in the OPC group, probably owing to increased use of hospice facilities. However, in multivariable analysis, only education level was associated with inpatient days during the last months, which implies hospitalization near death was more strongly influenced by socioeconomic aspects, rather than palliative care in this study.
Chemotherapy within 30 days from death was rarely administered to either of the study groups-2% in the OPC group and 9% in the non-OPC group. During the last 14 days, chemotherapy was applied in only 5% (4 patients) of the non-OPC group and none in the OPC group. Chemotherapy use near death tended to be more frequent in the non-OPC group than the OPC group, although the overall utilization rates of chemotherapy in this period (6%, 8 of 132 patients during the last 30 days) were too low to show a statistically significant difference between the groups. These findings contrast with the results from other Korean studies, wherein utilization rates for chemotherapy within 30 days from death reach 30%. 11, 13 This discrepancy is based on the fact that our study included deaths outside the hospital and in-hospital deaths, whereas other studies only report data derived from in-hospital deaths at tertiary cancer centers. 11, 13 The ED visit didn't show significantly statistical difference between the OPC and the non-OPC groups. This could be explained by small sample size and lack of home care service for the terminally ill patients. Although studies have shown that the implementation of palliative care was associated with reduce ED visits in EOL period, 27 ,28 the contents of palliative care might matter. Many ED visits of patients with cancer in EOL periods are known to be avoidable, such as uncontrolled pain, constipation, medication refill, and so on, which can be managed at outpatient clinic, 29 patients and family might benefit further from support at home such as 24/7 phone call or home hospice care. 30 Unfortunately, home hospice service is not yet established in Korea.
In the present study, we noted an imbalance in the types of chemotherapy used between the 2 study groups, despite similar baseline characteristics. Herein, targeted agents were more frequently used in the non-OPC group than the OPC group. On this, we offer the following explanation-targeted agents for mCRC were not covered by the national health insurance agency in Korea until March 2014. Accordingly, patients who received treatment with targeted agents despite the financial burden might have delayed seeking OPC, possibly due to beliefs in the curative potential of the treatment or inaccurate perceptions of their prognosis. Meanwhile, patients with more receptive attitudes to palliative care might have been selected for referral to OPC.
Several limitations to this study warrant consideration. First, the number of study participants was small, and information on patients who utilized other medical facilities was unavailable. Therefore, the generalizability of our results is limited. Second, patient-reported outcomes were not analyzed in this study, because quality of life and symptoms were checked irregularly with different scales at outpatient visits. Finally, patient perceptions of prognosis, goals of treatment, and financial standing were not considered. This could have influenced attendance to OPC or the utilization of hospice care. Despite these limitations, however, our study is meaningful in that we evaluated the associations of OPC with aggressiveness of EOL care in Korea, where the overutilization of ineffective practice near death is quite prevalent.
